Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma

December 7th 2025

The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

December 7th 2025

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

December 7th 2025

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT

December 6th 2025

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Odronextamab Plus CHOP Produces Deep, Potentially Durable Responses in Previously Untreated DLBCL

December 6th 2025

Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.

Survival in Induction Chemotherapy AML Studies May be Predictable by MRD

December 6th 2025

Future AML study analyses may focus on measurable residual disease to predict OS through non-intensive modern treatment backbones.

Race Is Predictive of Survival Outcomes With Intensive Chemotherapy Independent of Cytogenetics in AML

December 6th 2025

Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.

Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression

December 6th 2025

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Families Face Financial Hardships in Pediatric ALL

December 6th 2025

Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.

TBI-Free Conditioning Maintains Strong Outcomes in Pediatric and Young Adult B-Cell ALL

December 6th 2025

The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.

Loncastuximab Tesirine Plus Glofitamab Yields High CR Rates in DLBCL in Updated LOTIS-7 Analysis

December 4th 2025

Adding loncastuximab tesirine to glofitamab led to activity irrespective of disease status in relapsed/refractory diffuse large B-cell lymphoma.

Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025

December 3rd 2025

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

December 3rd 2025

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

NICE Recommends Obe-Cel for Adult R/R B-ALL

December 1st 2025

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

CLN-049 Nets FDA Fast Track Designation in Relapsed/Refractory AML

December 1st 2025

The FDA granted fast track designation to CLN-049 for relapsed/refractory acute myeloid leukemia.